Finally, current treatments of primary or relapsed/refractory [10, 11] ALK-positive ALCL induce tumor cell death in an immunogenic fashion, thus enhancing the immune-mediated control of tumor growth [12, 13]. The gene discussed is ALK; the disease is anaplastic large cell lymphoma.